The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those who have already received pre-erythrocytic ...

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new ...

NIH researchers identified MAD21-101, a novel antibody targeting a previously unexplored epitope on the malaria parasite.

Novel antibodies have the potential to pave the way for the next generation of malaria interventions. Researchers at the ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.

A recent study carried out by researchers in Burkina Faso and the UK, and published in The Lancet Infectious Diseases, has shown that the first blood-stage malaria vaccine, RH5.1/Matrix-M ...

The discovery of the pGlu-CSP epitope opens up new avenues for developing next-generation malaria vaccines and treatments.

New antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody ...